FDA Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergies
Dynavax Reports Interim, One-Year Data From Ragweed Allergy Trial at AAAAI
March 15th, 2007
Dynavax Technologies Corporation (NASDAQ:DVAX) reported interim data from the first year of its two-year ragweed allergy trial known as DARTT, including a prespecified regional analysis of sites that clearly showed a therapeutic benefit of TOLAMBA in the Midwest. These data and the results of an in-depth analysis of 716 evaluable patients at 30 U.S. centers will be presented by Dr. Eduardo Martins, Dynavax VP, Clinical Development, on Saturday, February 24, at 2:30 p.m. PST, at the AAAAI Annual Meeting in San Diego. As previously reported on January 8, Dynavax's analysis of total nasal symptom scores (TNSS) in the overall study population indicated that only minimal...
Source: FDA Law Weekly (2007-03-15)
|
